November 10, 2020 : Issue #1079

DISASTERS AVERTED — Near Miss Case Studies

Hemoglobin Abnormalities Affect A1c Testing

TOP STORIES — Diabetes News and Research

Sitagliptin Associated With Reduced Mortality In Diabetes Patients With COVID-19

Hybrid Closed-Loop Insulin Delivery for Children

Impaired Cognitive Function in Children With Type 1 Diabetes 

MOST POPULAR ARTICLES OF THE MONTH

#1 Pumping Up with Protein: Does This Work for Exercise and Health?

#2 The Promising Future of Oral Insulin

#3 Low Carbohydrate Diets the Future for Weight Loss in Obesity

Every day brings a record amount of newly diagnosed cases of COVID-19 and a corresponding surge in hospitalizations. This is of particular concern to our patients with diabetes, as the chances of hospitalization are increased. There have been many “quick fixes” pushed out to people without a lot of science, and many patients have had to reduce their diabetes care because of costs. This week our intern, Destiny Reed, from FAMU College of Pharmacy, is presenting information on how a common diabetes drug can reduce the risk of hospitalizations in our insulin using patients.

Click here to find out what medication is making our patients safer.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

I recently saw a patient for a diabetes follow-up and had just gotten her lab values faxed over. Her A1c came back at 9.6, despite the patient telling me that her glucose meter readings were much lower. She even showed me the meter, and upon doing some averaging, it appeared that her A1c should be a lot lower….

Patients taking the DPP-4 inhibitor sitagliptin had lower risk of needing intensive care or needing mechanical ventilation. 

Young children with type 1 diabetes often experience greater insulin variability, leading to more complications and a subpar quality of life.

The growing brain is more susceptible to adverse effects from glucose variability.